SCHEDULE 13G: BlackRock Discloses 6.3% Stake in Tango Therapeutics

BlackRock, Inc. has reported a 6.3% beneficial ownership stake in Tango Therapeutics, Inc., holding 8,477,165 shares of common stock as of December 31, 2025.

Summary

• BlackRock, Inc. beneficially owns 8,477,165 shares of Tango Therapeutics, Inc. common stock.
• This represents a 6.3% stake in the company's common stock.
• BlackRock holds sole voting power over 8,351,821 shares and sole dispositive power over 8,477,165 shares.
• The filing indicates that the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Tango Therapeutics.
• The filing was made under Rule 13d-1(b), identifying BlackRock as a parent holding company or control person.

Sentiment

Score: 7

Explanation: BlackRock's disclosure of a 6.3% passive stake in Tango Therapeutics, Inc. indicates a substantial investment by a leading global asset manager, which can be interpreted as a vote of confidence in the company's long-term prospects.

Positives

• Significant institutional investment from BlackRock, a major global asset manager, potentially signaling confidence in Tango Therapeutics.
• BlackRock's passive investment stance (not seeking control) suggests a long-term, fundamental investment perspective.

Negatives

• The filing itself does not contain any negative information regarding Tango Therapeutics' performance or outlook.

Risks

• The filing does not detail specific risks related to Tango Therapeutics' operations or financial health; it is a disclosure of ownership.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding Tango Therapeutics, Inc.'s future performance or strategic direction.

Management Comments

• To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

BlackRock, Inc. is one of the world's largest asset managers, and its disclosure of a significant stake in Tango Therapeutics, Inc. reflects its routine investment activities across various public companies. Such filings are common for large institutional investors that cross the 5% beneficial ownership threshold in publicly traded companies.

Comparison to Industry Standards

• This filing is a standard disclosure of beneficial ownership by a large institutional investor. It does not contain information that allows for a direct comparison of Tango Therapeutics' results to industry benchmarks or specific comparable companies/projects.

Stakeholder Impact

• Shareholders: BlackRock's significant stake could be viewed positively, potentially increasing investor confidence and liquidity.
• Management: The passive nature of the investment suggests no immediate pressure for strategic changes from BlackRock.

Key Dates

Keywords

BlackRock, Tango Therapeutics, Schedule 13G, beneficial ownership, institutional investor, common stock, equity stake, passive investment, asset management